Evolution of Early-Phase Anticancer Drug Investigations in China

JAMA Oncol. 2022 Nov 1;8(11):1692-1694. doi: 10.1001/jamaoncol.2022.3856.

Authors

Shuhang Wang¹, Yue Yu¹, Yale Jiang¹, Huishan Zhang², Peiwen Ma¹, Gang Liu³, Ning Li¹

Affiliations

¹ Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Phase I Clinical Trial Ward, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Province, China.
³ Key Laboratory of Molecular Epigenetics of the Ministry of Education, Northeast Normal University, Changchun, China.

No abstract available

Plain language summary

This study examines phase 1 anticancer drug clinical trials performed in China from 2017 to 2021.

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
China
Humans

Substances

Antineoplastic Agents